Kisqali is indicated in combination with:

a non-steroidal aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2

(HER2)-negative locally advanced or metastatic breast cancer, as initial endocrine-based therapy; or 

fulvestrant for the treatment of men and postmenopausal women with HR-positive, HER2- negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

×

Medical Information Request

×

Ask Speakers